Thomas Trimarchi sold $1.1M of BBIO
President and CFO at BridgeBio Pharma, Inc.. 16,934 shares at an average of $66.46, traded Nov 17, 2025, filed Nov 18, 2025.
Score components
- +22RoleCFO
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 4.2% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-25-000351, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 16, 2025 | FTax withholding Common Stock10b5-1 | -21,317 | $66.39 | $1.4M | 399,764 | Nov 18, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -9,978 | $66.19 | $660k | 389,786 | Nov 18, 2025 |
| Nov 17, 2025 | SOpen-market sale Common Stock10b5-1 | -6,956 | $66.84 | $465k | 382,830 | Nov 18, 2025 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.5M 80,000 shares | -12% | |
| 35Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $624k 8,671 shares | -54% | |
| 40Moderate | BridgeBio Pharma, Inc. | Andrea Ellis director | $4.2M 64,921 shares | -78% | |
| 40Moderate | BridgeBio Pharma, Inc. | Hannah Valantine director | $1.7M 25,484 shares | -77% | |
| 21Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $132k 2,000 shares | -2% | |
| 50Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $2.0M 28,053 shares | -11% | |
| 16Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $38k 510 shares | -0% | |
| 27Weak | BridgeBio Pharma, Inc. | Randal W. Scott director | $755k 10,000 shares | -46% | |
| 42Moderate | BridgeBio Pharma, Inc. | Thomas Trimarchi President and CFO | $1.0M 13,600 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.